Structure

InChI Key JWAZHODZSADEHB-UHFFFAOYSA-M
Smile CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)[O-].C[N+](C)(C)CCO
InChI
InChI=1S/C17H15ClO4.C5H14NO/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11;1-6(2,3)4-5-7/h3-10H,1-2H3,(H,20,21);7H,4-5H2,1-3H3/q;+1/p-1

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H28ClNO5
Molecular Weight 421.92
AlogP 3.81
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 5.0
Polar Surface Area 63.6
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 22.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Peroxisome proliferator-activated receptor alpha agonist DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lipid Metabolism Disorders 3 D052439 ClinicalTrials
Hypercholesterolemia 3 D006937 ClinicalTrials
Hyperlipidemia, Familial Combined 3 D006950 ClinicalTrials
Coronary Disease 3 D003327 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
11.14
Injury, poisoning and procedural complications
8.93
General disorders and administration site conditions
8.61
Gastrointestinal disorders
8.29
Musculoskeletal and connective tissue disorders
7.98
Vascular disorders
5.61
Respiratory, thoracic and mediastinal disorders
5.37
Blood and lymphatic system disorders
5.21
Investigations
5.21
Psychiatric disorders
5.13
Cardiac disorders
3.87
Skin and subcutaneous tissue disorders
3.87
Infections and infestations
3.4
Metabolism and nutrition disorders
3.16
Renal and urinary disorders
2.84
Hepatobiliary disorders
2.21

Cross References

Resources Reference
ChEMBL CHEMBL1201745
EPA CompTox DTXSID50234939
FDA SRS 4BMH7IZT98
Guide to Pharmacology 2662
PubChem 11350701
ZINC ZINC00001984